Cary Street Partners Financial LLC Takes $3.36 Million Position in BWX Technologies, Inc. $BWXT

Cary Street Partners Financial LLC purchased a new stake in BWX Technologies, Inc. (NYSE:BWXT) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 19,418 shares of the technology company’s stock, valued at approximately $3,356,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Aventura Private Wealth LLC acquired a new stake in BWX Technologies in the fourth quarter valued at approximately $29,000. WFA of San Diego LLC acquired a new position in shares of BWX Technologies during the second quarter worth $29,000. Strategic Advocates LLC purchased a new position in shares of BWX Technologies in the third quarter valued at $32,000. Tucker Asset Management LLC purchased a new position in shares of BWX Technologies in the fourth quarter valued at $36,000. Finally, Strategic Investment Solutions Inc. IL grew its holdings in BWX Technologies by 300.0% during the 3rd quarter. Strategic Investment Solutions Inc. IL now owns 200 shares of the technology company’s stock valued at $37,000 after purchasing an additional 150 shares in the last quarter. Institutional investors and hedge funds own 94.39% of the company’s stock.

BWX Technologies Trading Down 2.6%

NYSE BWXT opened at $199.04 on Thursday. The company has a market capitalization of $18.23 billion, a price-to-earnings ratio of 53.22, a price-to-earnings-growth ratio of 3.37 and a beta of 0.78. The company has a debt-to-equity ratio of 1.58, a current ratio of 2.40 and a quick ratio of 2.33. BWX Technologies, Inc. has a 12 month low of $123.06 and a 12 month high of $241.82. The company’s fifty day moving average price is $213.42 and its two-hundred day moving average price is $199.59.

BWX Technologies (NYSE:BWXT) last released its earnings results on Monday, May 4th. The technology company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.20. The company had revenue of $860.22 million during the quarter, compared to the consensus estimate of $837.47 million. BWX Technologies had a net margin of 10.20% and a return on equity of 31.33%. The company’s revenue was up 26.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.91 EPS. BWX Technologies has set its FY 2026 guidance at 4.600-4.750 EPS. As a group, research analysts predict that BWX Technologies, Inc. will post 4.71 earnings per share for the current fiscal year.

BWX Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Tuesday, May 19th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, May 19th. BWX Technologies’s payout ratio is currently 28.88%.

Insider Buying and Selling at BWX Technologies

In other BWX Technologies news, CAO Kevin James Gorman sold 1,344 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $214.71, for a total transaction of $288,570.24. Following the transaction, the chief accounting officer owned 114 shares of the company’s stock, valued at $24,476.94. This trade represents a 92.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Rex D. Geveden sold 10,000 shares of BWX Technologies stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $204.81, for a total value of $2,048,100.00. Following the completion of the transaction, the chief executive officer owned 202,491 shares of the company’s stock, valued at approximately $41,472,181.71. The trade was a 4.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,761 shares of company stock worth $2,842,427 over the last quarter. 0.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on BWXT. TD Cowen initiated coverage on shares of BWX Technologies in a report on Thursday, March 12th. They issued a “buy” rating and a $230.00 price objective on the stock. TD Securities began coverage on BWX Technologies in a research note on Thursday, March 12th. They set a “buy” rating and a $230.00 target price for the company. Bank of America lifted their target price on BWX Technologies from $230.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reissued a “buy (b-)” rating on shares of BWX Technologies in a report on Friday, May 22nd. Finally, BTIG Research raised their price objective on BWX Technologies from $225.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $228.00.

BWX Technologies Company Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non?defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.